Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07807839

Study of Correlation Between Serum BDNF Levels and Pfirmann Grading and IL- 1β

Brain-derived neurotrophic factor (BDNF) is a protein belonging to the neurotrophin family, known to be involved in neuronal survival, growth, and synaptic plasticity. Recent studies suggest that the role of BDNF may extend beyond the central nervous system to include inflammatory responses and degenerative changes in peripheral tissues. In particular, BDNF expression has been confirmed within intervertebral disc tissue, with degenerated discs showing increased BDNF expression compared to normal discs, and this expression has been reported to increase further with the severity of degeneration Intervertebral disc degeneration is closely associated with intradiscal nerve ingrowth (neoinnervation) and the resulting generation of pain, and BDNF has been reported as a factor mediating this nerve ingrowth and pain sensitization (central/peripheral sensitization) within the disc. Interleukin-1 beta (IL-1β), a representative inflammatory cytokine of disc degeneration, is known as a key mediator that promotes extracellular matrix degradation within disc tissue and induces neoinnervation and sensitization. Because BDNF secretion from neurons and immune cells has also been reported to increase in inflammatory environments, a potential interaction between IL-1β and BDNF has been proposed Accordingly, this study aims to measure serum BDNF concentrations in patients presenting with low back and leg pain due to disc degeneration or spinal stenosis, and to analyze whether these levels show a consistent correlation with Pfirrmann grading on MRI and serum IL-1β concentration.

Recruiting

Interested in participating?

Request Info

Key information

Age range

20 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • lumbar disc herniation
  • lumbar spinal canal stenosis
  • patients who have MRI

Exclusion criteria

  • spine fracture
  • spine infection
  • spine tumor
  • rhematoid arthritis
  • ankylosing spondylitis
  • systemic lupus erythematosus
  • peripheral neuropathy
  • fibromyalgia
  • patient taking antidepressant, antipsychotics, acetylcholiesterase inhibitor

Treatment and study plan

blood sampling for ELISA

Procedure

blood sampling to detect the level of BDNF

Primary outcomes

  1. Idenfifying the correlation of BDNF level and Pfirmann grading

    Time frame: day 1

Secondary outcomes

  1. Idnetifying the correlation of BDNF level and IL-1β

    Time frame: day 1

Study contacts

Contact information is provided by the study sponsor or research team.

JIHEE Hong

CONTACT

[email protected]

01046794343

Sponsors and collaborators

Lead sponsor

Keimyung University Dongsan Medical Center

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Sep 8, 2026
Registry last updated
Sep 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.